| NH3 Clean Energy Limited (NH3) ORDINARY FULLY PAID |
Materials |
$68 |
Half Yearly Report and Accounts
|
16 Mar 2026 8:37AM |
$0.088 |
$0.095 |
risen by
7.95%
|
|
| Perpetual Limited (PPT) ORDINARY FULLY PAID |
Financials |
$1,908 |
Sale of Wealth Management business
|
16 Mar 2026 8:36AM |
$16.240 |
$16.500 |
risen by
1.60%
|
|
PPT - Price-sensitive ASX Announcement
Full Release
Key Points
- Perpetual Limited is selling its Wealth Management business.
- The sale is part of a strategy to simplify and strengthen the company.
- Completion is expected by the end of 2026.
- The transaction requires regulatory and court approvals.
- Estimated transaction costs are approximately $30 million post-tax.
- Estimated tax on proceeds is between $45-50 million.
- Net proceeds will be used to repay debt.
- The sale does not have a financing condition.
- Transitional services will be provided for up to 18 months.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Koonenberry gold Limited (KNB) ORDINARY FULLY PAID |
Materials |
$26 |
Half Yearly Report and Accounts
|
16 Mar 2026 8:35AM |
$0.024 |
$0.025 |
risen by
4.17%
|
|
| Dyno Nobel Limited (DNL) ORDINARY FULLY PAID |
Materials |
$5,600 |
Update - Notification of buy-back - DNL
|
16 Mar 2026 8:35AM |
$3.000 |
$3.190 |
risen by
6.33%
|
|
| Calix Limited (CXL) ORDINARY FULLY PAID |
Materials |
$121 |
First ARENA grant milestone for Zesty complete
|
16 Mar 2026 8:35AM |
$0.680 |
$0.560 |
fallen by
17.65%
|
|
CXL - Price-sensitive ASX Announcement
Full Release
Key Points
- Calix Limited completes first ARENA grant milestone for Zesty.
- This milestone triggers a $2 million cash payment from ARENA.
- The project is known as the Zesty Green Iron Demonstration Project.
- A total of $42.9 million in further ARENA grant payments remain pending.
- Calix received a $3 million payment from Rio Tinto in December 2025.
- Over $32 million remains outstanding from Rio Tinto under a Joint Development Agreement.
- Calix's core technology involves indirect heating for renewably powered processes.
- The project remains on schedule with technical and commercial progress.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aurizon Holdings Limited (AZJ) ORDINARY FULLY PAID |
Industrials |
$7,003 |
Update - Notification of buy-back - AZJ
|
16 Mar 2026 8:30AM |
$4.000 |
$4.160 |
risen by
4%
|
|
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$2,618 |
Net Tangible Asset Backing
|
16 Mar 2026 8:30AM |
$4.050 |
$4.130 |
risen by
1.98%
|
|
| Strike Energy Limited (STX) ORDINARY FULLY PAID |
Energy |
$414 |
South Erregulla Power Project Update
|
16 Mar 2026 8:30AM |
$0.110 |
$0.115 |
risen by
4.55%
|
|
STX - Price-sensitive ASX Announcement
Full Release
Key Points
- 35% increase in BRCP for 2028/29 to $488,500 per MW per annum.
- 15 km single circuit overhead power line completed.
- Power station work package nearing completion.
- Dry commissioning activities have commenced.
- Project on track for completion by October 1, 2026.
- Strike expects full 85 MW capacity allocation for 2028/29.
- Project supports system reliability and renewable integration within WA's electricity market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| DataWorks Group Limited (DWG) ORDINARY FULLY PAID |
Information Technology |
$14 |
Update on Strategic Process
|
16 Mar 2026 8:30AM |
$0.125 |
$0.135 |
risen by
8%
|
|
DWG - Price-sensitive ASX Announcement
Full Release
Key Points
- DataWorks Group Limited (ASX: DWG) is undergoing a strategic review process.
- Tekkorp Capital Advisors have been appointed to assist with assessing strategic interest in DataWorks' assets.
- The strategic review is ongoing with multiple parties engaged in discussions.
- Discussions are preliminary and non-binding, exploring various strategic options.
- DataWorks' technology, regulatory relationships, and international opportunities are considered valuable.
- There is no certainty that the review will result in any transactions or proposals.
- DataWorks commits to keeping the market informed according to disclosure obligations.
- DataWorks specializes in regulated gaming technology, notably the BetStopâ„¢ National Self-Exclusion Register.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gateway Mining Limited (GML) ORDINARY FULLY PAID |
Materials |
$163 |
Drilling Commenced at Great Western
|
16 Mar 2026 8:30AM |
$0.074 |
$0.070 |
fallen by
5.41%
|
|
GML - Price-sensitive ASX Announcement
Full Release
Key Points
- Drilling has commenced at Gateway's top priority, the Great Western gold target.
- This is the first systematic drilling program at the Great Western site.
- The site features a 16 km dolerite strike length with gold-in-soil anomalies.
- Gateway is well-capitalised, with significant cash reserves and liquid assets.
- The drilling program is expected to take three months to complete.
- Great Western displays geological similarities to significant Eastern Goldfields deposits.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PTR Minerals Ltd (PTR) ORDINARY FULLY PAID |
Materials |
$37 |
Positive Metallurgical Performance and Strong Drill Results
|
16 Mar 2026 8:30AM |
$0.185 |
$0.093 |
fallen by
49.73%
|
|
PTR - Price-sensitive ASX Announcement
Full Release
Key Points
- Positive metallurgical performance at Rosewood project.
- High recovery of Heavy Minerals through conventional processing.
- Production of high-grade titanium products.
- Strong drill results indicating high-grade mineralisation.
- Ongoing metallurgical and processing evaluation activities.
- Resource estimation planned for Q2 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Narryer Metals Limited (NYM) ORDINARY FULLY PAID |
Materials |
$13 |
PTR: Positive Metallurgical Perf.and Strong Drill Results
|
16 Mar 2026 8:30AM |
$0.020 |
$0.064 |
risen by
220%
|
|
NYM - Price-sensitive ASX Announcement
Full Release
Key Points
- Positive metallurgical performance
- Strong drilling results in Rosewood Titanium Project
- Batch 4 shows high-grade mineralisation
- Large bulk sample RM04 confirms high-grade average
- Continued exploration and metallurgical testing
- Focus on economic and development potential
- Plant design and preliminary cost assessments underway
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dimerix Limited (DXB) ORDINARY FULLY PAID |
Health Care |
$144 |
Dimerix to Conduct Review of ACTION3 Statistical Assumptions
|
16 Mar 2026 8:29AM |
$0.350 |
$0.240 |
fallen by
31.43%
|
|
DXB - Price-sensitive ASX Announcement
Full Release
Key Points
- Dimerix Limited to conduct a blinded review of ACTION3 Phase 3 study data to confirm statistical assumptions.
- The blinded review will verify the study remains adequately powered for its primary endpoint.
- The ACTION3 Phase 3 study focuses on the efficacy and safety of DMX-200 in patients with FSGS.
- The study has passed several reviews with no safety issues or protocol changes requested.
- FDA has confirmed the primary endpoint's suitability for supporting traditional approval.
- The review aims to ensure the study can demonstrate a treatment effect without revealing treatment assignments.
- Results from the review are expected to be available in April 2026.
- DMX-200, a chemokine receptor antagonist, is under development for treatment in conjunction with existing hypertension therapies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Flagship Minerals Limited (FLG) ORDINARY FULLY PAID |
Materials |
$84 |
Corporate Presentation
|
16 Mar 2026 8:29AM |
$0.295 |
$0.260 |
fallen by
11.86%
|
|
| Syrah Resources Limited (SYR) ORDINARY FULLY PAID |
Materials |
$254 |
Tesla offtake alleged default cure date extended
|
16 Mar 2026 8:28AM |
$0.170 |
$0.110 |
fallen by
35.29%
|
|
SYR - Price-sensitive ASX Announcement
Full Release
Key Points
- Syrah Resources faces an alleged default under the Tesla offtake agreement.
- Original cure date set for March 16, 2026.
- Cure date extended to June 1, 2026.
- Extension subject to United States Department of Energy consent.
- Collaboration between Syrah and Tesla to resolve the issue.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Red Mountain Mining Limited (RMX) ORDINARY FULLY PAID |
Materials |
$18 |
Half Yearly Report and Accounts
|
16 Mar 2026 8:27AM |
$0.024 |
$0.019 |
fallen by
20.83%
|
|
| BNK Banking Corporation Limited (BBC) ORDINARY FULLY PAID |
Financials |
$28 |
Notification of cessation of securities - BBC
|
16 Mar 2026 8:27AM |
$0.280 |
$0.235 |
fallen by
16.07%
|
|
| South32 Limited (S32) ORDINARY FULLY PAID |
Materials |
$19,337 |
Mozal Aluminium Placed on Care and Maintenance
|
16 Mar 2026 8:24AM |
$4.410 |
$4.310 |
fallen by
2.27%
|
|
| Minerals 260 Limited (MI6) ORDINARY FULLY PAID |
Materials |
$1,652 |
Euroz Hartleys Conference and Site Visit Presentation
|
16 Mar 2026 8:22AM |
$0.620 |
$0.730 |
risen by
17.74%
|
|
| Nova Minerals Limited (NVA) ORDINARY FULLY PAID |
Materials |
$299 |
Nova Winter Freight Haul Underway
|
16 Mar 2026 8:20AM |
$0.765 |
$0.655 |
fallen by
14.38%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,096 |
Annual General Meeting and Director Nominations
|
16 Mar 2026 8:20AM |
$4.510 |
$4.890 |
risen by
8.43%
|
|
| Orora Limited (ORA) ORDINARY FULLY PAID |
Materials |
$1,734 |
Update - Notification of buy-back - ORA
|
16 Mar 2026 8:19AM |
$1.905 |
$1.415 |
fallen by
25.72%
|
|
| Guzman Y Gomez Limited (GYG) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,856 |
GYG Co-CEO Update
|
16 Mar 2026 8:19AM |
$18.050 |
$18.330 |
risen by
1.55%
|
|
| Neurizon Therapeutics Limited (NUZ) ORDINARY FULLY PAID |
Health Care |
$65 |
Neurizon announces leadership transition
|
16 Mar 2026 8:19AM |
$0.096 |
$0.087 |
fallen by
9.38%
|
|
NUZ - Price-sensitive ASX Announcement
Full Release
Key Points
- Neurizon Therapeutics Limited announced a leadership transition.
- Dr. Michael Thurn resigned as Managing Director and Chief Executive Officer.
- Dr. Thurn's resignation is effective from 16 March 2026, with a notice period until July 2026.
- During the transition, Dr. Thurn will continue as a Non-Executive Director.
- Mr. Sergio Duchini will serve as Interim Executive Chair until a new CEO is appointed.
- A global search for a new CEO is underway with the help of Coulter Partners.
- Neurizon Therapeutics is a clinical-stage biotechnology company focused on treatments for neurodegenerative diseases.
- The company is advancing its lead drug candidate, NUZ-001, for the treatment of ALS.
- NUZ-001 is not yet approved for commercial use.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$4,999 |
Telix Resubmits NDA to FDA for Pixclara Brain Cancer Imaging
|
16 Mar 2026 8:19AM |
$11.290 |
$14.740 |
risen by
30.56%
|
|
TLX - Price-sensitive ASX Announcement
Full Release
Key Points
- Telix resubmits NDA for TLX101-Px to FDA.
- TLX101-Px is aimed at imaging recurrent/progressive gliomas.
- FDA requested additional data for the resubmission.
- TLX101-Px has orphan drug and fast track designations.
- The agent targets LAT1 for potential use in glioma diagnostics.
- Telix is collaborating globally for data on TLX101-Px.
- The company seeks to address unmet needs in brain cancer imaging.
- Telix operates globally with headquarters in Melbourne, Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.